https://www.thebodypro.com/category/genvoya-pro/tag/news

The Latest

human skeleton posed in thinking position

This Week in HIV Research: If I Could Turn Back Ossein

Nov. 7, 2019: Zoledronic acid to prevent bone loss; bone benefits for older patients switching from TDF to TAF; periperhal artery disease among women; motor dysfunction and cognitive impairment.

By Barbara Jungwirth and Myles Helfand
Contraception pills on blue background

This Week in HIV Research: Cracking the Contraception Conundrum

July 11, 2019: Seroconversion while on long-acting contraceptives; cardiovascular risk in people with HIV; suboptimal testing in high-prevalence U.S. areas; E/C/F/TAF may be suitable for PEP.

By Barbara Jungwirth and Myles Helfand
Putting test tubes into the holder

This Week in HIV Research: I Screen, You Screen, We All Screen for HPV-Related Cancers

May 23, 2019: How CD4 variables over time affect anal cancer risk; when to consider anal pap smears for women; switching from E/C/F/TAF to ABC/3TC; new data on marijuana use among people with HIV.

By Barbara Jungwirth and Myles Helfand
illustration of person on cliff with arms raised as sun rises/sets

This Week in HIV Research: From PrEP to Treatment, There's Always More to Learn

April 18, 2019: lamivudine/raltegravir for PrEP; feminizing hormone may impact PrEP efficacy; why TAF has a better renal profile than TDF; the role of internet dating in HIV incidence trends.

By Barbara Jungwirth and Myles Helfand
TAF as Effective as TDF in Cisgender Women, With Fewer Side Effects Img

TAF as Effective as TDF in Cisgender Women, With Fewer Side Effects

A pooled analysis presented at CROI 2019 showed fewer kidney and bone density issues with tenofovir alafenamide in cisgender women than were found with the older formulation.

By Martha Kempner
Promo Image

This Week in HIV Research: Renal Upsides for Tenofovir Alafenamide

E/C/F/TAF viability for dialysis patients; TAF safety following renal damage; mental health needs for American Indians; parenting desires of people with HIV.

By Barbara Jungwirth and Myles Helfand
FDA Approved Changes to the Genvoya Label Img

FDA Approved Changes to the Genvoya Label

FDA recently approved changes to the Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) fixed-dose combination tablet product labeling.

By U.S. Food and Drug Administration
Genvoya Approved in Canada: What You Need to Know Img

Genvoya Approved in Canada: What You Need to Know

Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) is a complete treatment in one pill that comes in the form of green capsule-shaped tablets. The dose of Genvoya used by adults with HIV is one tablet once daily with food.

By Sean R. Hosein for Canadian AIDS Treatment Information Exchange
Tenofovir Alafenamide (TAF) Is Coming Img

Tenofovir Alafenamide (TAF) Is Coming

The first TAF-containing medicine, Genvoya, was licensed by the U.S. Food and Drug Administration (FDA) in November 2015 and will likely be licensed by Health Canada late in 2015.

By Sean R. Hosein for Canadian AIDS Treatment Information Exchange
New HIV Treatment Genvoya Is Really All About the TAF Part Img

New HIV Treatment Genvoya Is Really All About the TAF Part

With the FDA approval of Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide), we now have a fifth one-pill-a-day treatment for HIV. On the surface, the only thing new here is the tenofovir alafenamide (TAF) component. So what does T...

By Paul E. Sax, M.D. for NEJM Journal Watch